Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MATULANE vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Treatment of advanced Hodgkin lymphoma (in combination with other drugs),Treatment of non-Hodgkin lymphoma (off-label),Treatment of brain tumors (off-label)
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Procarbazine is metabolized primarily by the liver via oxidation by CYP450 enzymes and other oxidases to active metabolites. It also undergoes some metabolism by monoamine oxidase (MAO) in the liver and other tissues.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 10-20% bound to plasma proteins (mainly albumin); minimal binding.
47% bound to plasma proteins (primarily albumin)
Approximately 3-4 L/kg; indicates extensive tissue distribution including brain (penetrates CNS).
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral bioavailability is nearly complete (close to 100%) after oral administration.
IV: 100% (only IV route); oral: not approved
GFR ≥50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose to 50-75%; GFR <10 m L/min: avoid use or reduce to 50% and monitor.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Child-Pugh A: 100% of dose; Child-Pugh B: reduce by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Based on BSA: 100 mg/m2 orally once daily for 14 days as part of MOPP; or 50 mg/m2 orally on days 1-14.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
Start at lower end of dosing range (e.g., 200 mg daily) due to increased risk of myelosuppression and renal/hepatic impairment; monitor CBCs closely.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
Procarbazine is carcinogenic, mutagenic, and teratogenic. It should be used only by physicians experienced in cancer chemotherapy. Patients receiving procarbazine should be carefully monitored for hematologic toxicity.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Bone marrow suppression (leukopenia, thrombocytopenia, anemia) requires dose adjustment; discontinue if toxicity is severe. CNS effects (drowsiness, depression, confusion) may occur. Disulfiram-like reaction with alcohol. Hypertensive crisis can occur with tyramine-rich foods or sympathomimetics due to MAO inhibition. Monitor for secondary malignancies. Fetal harm can occur; avoid pregnancy.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to procarbazine; concomitant use with MAO inhibitors, tricyclic antidepressants, or other drugs with MAO-inhibiting activity; severe bone marrow depression; pregnancy.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Avoid tyramine-rich foods: aged cheeses (cheddar, Swiss), cured meats (salami, pepperoni), fermented soy products (tofu, miso), sauerkraut, pickled herring, broad bean pods, yeast extracts, red wine, beer, and draft beers. Also avoid alcohol completely due to additive CNS depression.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Matulane (procarbazine) is a known teratogen. First trimester exposure is associated with major congenital malformations. Second and third trimester exposure carries risk of intrauterine growth restriction, fetal bone marrow suppression, and potential carcinogenesis. Use contraindicated in pregnancy.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Procarbazine is excreted into breast milk. M/P ratio not reported. Due to potential for carcinogenicity and adverse effects in the nursing infant, breastfeeding is contraindicated during matulane therapy and for at least 2 weeks after last dose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No well-established safe dose in pregnancy. If therapy is deemed essential despite risks, significant dose reduction and increased monitoring advised. Pharmacokinetic changes in pregnancy may alter procarbazine metabolism, but specific dose adjustments are not defined. Use only in life-threatening conditions with expert consultation.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Matulane (procarbazine) is a monoamine oxidase inhibitor (MAOI); concurrent use with sympathomimetics, tyramine-rich foods, or tricyclic antidepressants can precipitate hypertensive crisis. It is also a potent CNS depressant; avoid alcohol. Monitor for leukopenia and thrombocytopenia; nadir typically occurs 2-4 weeks after therapy. Discontinue if hypersensitivity pneumonitis occurs.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Avoid foods high in tyramine such as aged cheeses, cured meats, fermented foods, and alcoholic beverages (especially beer and red wine) to prevent severe high blood pressure.,Do not take any over-the-counter medications, especially cold, sinus, or allergy medications, without consulting your doctor due to risk of drug interactions.,This drug may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or shortness of breath immediately.,Use effective contraception during treatment and for at least 1 month after stopping, as this drug can harm an unborn baby.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MATULANE vs CLOFARABINE, answered by our medical review team.
MATULANE is a Antineoplastic Agent that works by Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MATULANE and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MATULANE is: 200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MATULANE and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MATULANE is classified as Category C. Matulane (procarbazine) is a known teratogen. First trimester exposure is associated with major congenital malformations. Second and third trimester exposure carries risk of intrau. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.